HIV Pre-Exposure Prophylaxis Linked to Drop in Condom Use

This article originally appeared here.
Share this content:
HIV Pre-Exposure Prophylaxis Linked to Drop in Condom Use
HIV Pre-Exposure Prophylaxis Linked to Drop in Condom Use

THURSDAY, June 7, 2018 (HealthDay News) -- For gay and bisexual men, an increase in HIV pre-exposure prophylaxis (PrEP) is associated with a reduction in condom use, according to a study published online June 6 in The Lancet HIV.

Martin Holt, Ph.D., from the University of New South Wales in Sydney, and colleagues analyzed the uptake and effect of PrEP using data from the Melbourne and Sydney Gay Community Periodic Surveys (GCPS) of adult gay and bisexual men. Trends in condom use, condomless anal intercourse with casual partners (CAIC), and PrEP use by gay and bisexual men were assessed.

Overall, 27,011 participants completed questionnaires in the Melbourne and Sydney GCPS between Jan. 1, 2013, and March 31, 2017. The researchers found that 1 percent of 2,692 men reported CAIC, were HIV-negative, and used PrEP in 2013, compared with 5 percent of 3,660 men in 2016 and 16 percent of 4,018 men in 2017 (P < 0.001). Consistent condom use was reported by 46, 42, and 31 percent of men in 2013, 2016, and 2017, respectively (P < 0.001). Thirty percent of men who were HIV-negative or untested and not on PrEP reported CAIC in 2013, compared with 31 and 29 percent of men in 2016 and 2017, respectively (non-significant trend).

"Other jurisdictions should consider the potential for community-level increases in CAIC when modelling the introduction of PrEP and in monitoring its effect," the authors write.

Two authors disclosed financial ties to Gilead Sciences, the manufacturer of the PrEP medication Truvada.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves First Customizable Insulin Pump

FDA Approves First Customizable Insulin Pump

Product works by delivering insulin under the skin at set or variable rates

Sepsis Common in Terminal Hospitalizations, Discharges

Sepsis Common in Terminal Hospitalizations, Discharges

Most common underlying causes of death in sepsis are solid and hematologic cancers, chronic heart disease

Fewer Older Men Assessed, Treated for Osteoporosis

Fewer Older Men Assessed, Treated for Osteoporosis

Fewer older men than women, even with higher risk, undergo DXA screening, 25(OH)D measurement

is free, fast, and customized just for you!




Already a member?

Sign In Now »